699800P
Avanti
MPLA (PHAD™)
Avanti Research™ - A Croda Brand
Synonym(s):
PHAD™ phosphorylated hexaacyl disaccharide; Glycopyranoside Lipid A; GLA
Sign Into View Organizational & Contract Pricing
Select a Size
All Photos(3)
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C96H184N3O22P
CAS Number:
Molecular Weight:
1763.47
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
Recommended Products
description
Monophosphoryl Lipid A (Synthetic) (PHAD™)
assay
>99% (HPLC)
form
powder
packaging
pkg of 1 × 1 mg (699800P-1mg)
pkg of 1 × 5 mg (699800P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
application(s)
vaccine development
shipped in
dry ice
storage temp.
−20°C
General description
Monophosphoryl lipid A (MPLA) is either extracted from bacterial lipid A or by chemical synthesis.[1]
Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant research.
Application
MPLA PHAD™ has been used:
- as a component of cobalt porphyrin-phospholipid (Co-PoP) liposomes for the immunization of mice with membrane proximal external region (MPER) of the gp41 envelope protein [2]
- as an adjuvant along with dimethyldioctadecylammonium bromide(DDA) for C. muridarum recombinant membrane protein based multi-subunit vaccine[3]
- as toll-like receptor-4 (TLR4) agonist adjuvant for respiratory syncytial virus (RSV) fusion (F) protein FI-RSV vaccine [4]
Biochem/physiol Actions
Packaging
2 mL Amber Glass Crimp Cap Vial (699800P-1mg)
2 mL Amber Glass Crimp Cap Vial (699800P-5mg)
Reconstitution
Soluble in ethanol at 1mg/mL, soluble in DMSO at 5mg/mL, soluble in Chloroform:Methanol:Water at 5mg/mL, insoluble in water (aqueous buffers, serum etc.); however, it can be dispersed in an aqueous medium using a suitable emulsifier or detergent. This species is soluble in chloroform (at least up to 50 mg/mL) and chloroform:methanol solvent systems, however gentle heating and sonication may be necessary to aid in dissolution. Dropwise additions of methanol or water may aid dissolution in chloroform at higher concentrations. If using in combination with other lipids, dissolve this lipid separately and then combine dissolved lipids in their respective solvent solutions.
Other Notes
For R&D use only. Not for drug, household, or other uses.
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
PHAD is a trademark of Avanti Polar Lipids, LLC
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Katharina Richard et al.
Vaccine, 38(27), 4298-4308 (2020-05-12)
Toll-like receptors (TLRs), a family of "pattern recognition receptors," bind microbial and host-derived molecules, leading to intracellular signaling and proinflammatory gene expression. TLR4 is unique in that ligand-mediated activation requires the co-receptor myeloid differentiation 2 (MD2) to initiate two signaling
Rhea N Coler et al.
PloS one, 6(1), e16333-e16333 (2011-02-08)
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I
Susana Lousada-Dietrich et al.
Vaccine, 29(17), 3284-3292 (2011-02-26)
GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant
Christopher B Fox et al.
Sub-cellular biochemistry, 53, 303-321 (2010-07-02)
Natural derivatives and synthetic analogues of lipopolysaccharide are potent stimulators of the mammalian immune system. Retained adjuvant activity with reduced toxicity was obtained by the development of monophosphoryl lipid A (MPL((R))), which is approved for use in several vaccine products.
Ryan C Anderson et al.
Colloids and surfaces. B, Biointerfaces, 75(1), 123-132 (2009-09-15)
Immunostimulatory molecules such as monophosphoryl lipid A (MPL), a Toll-like receptor 4 (TLR4) agonist, can be formulated to enhance vaccine adjuvant effects and to promote a Th1-type immune response. This study compares the in vitro and in vivo potency of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
